VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
Alimentation Couche-Tard Inc. vs Bristol-Myers Squibb Company
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Alimentation Couche-Tard Inc.
ATD · Toronto Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Alimentation Couche-Tard Inc.'s moat claims, evidence, and risks.
View ATD analysisBristol-Myers Squibb Company
BMY · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Bristol-Myers Squibb Company's moat claims, evidence, and risks.
View BMY analysisComparison highlights
- Moat score gap: Alimentation Couche-Tard Inc. leads (58 / 100 vs 56 / 100 for Bristol-Myers Squibb Company).
- Segment focus: Alimentation Couche-Tard Inc. has 3 segments (74% in Road transportation fuel (retail fuel and related mobility services)); Bristol-Myers Squibb Company has 5 segments (27.6% in Eliquis franchise (apixaban)).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Weak vs Moderate.
- Moat breadth: Alimentation Couche-Tard Inc. has 5 moat types across 2 domains; Bristol-Myers Squibb Company has 4 across 3.
Primary market context
Alimentation Couche-Tard Inc.
Road transportation fuel (retail fuel and related mobility services)
Road transportation fuel retail (gasoline/diesel) at convenience sites; includes unmanned/automated fuel stations
North America and Europe (plus select other regions via the network)
Consumers and small fleets
Fuel retailer and site operator
74%
Bristol-Myers Squibb Company
Eliquis franchise (apixaban)
Direct oral anticoagulants (DOACs) for stroke prevention in NVAF and treatment/prevention of DVT/PE
Global
Payers, PBMs, hospitals, clinics, pharmacies
Branded drug manufacturer (co-commercialization alliance)
27.6%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
Alimentation Couche-Tard Inc. strengths
Bristol-Myers Squibb Company strengths
Segment mix
Alimentation Couche-Tard Inc. segments
Full profile >Merchandise and services (in-store convenience retail)
Competitive
Road transportation fuel (retail fuel and related mobility services)
Competitive
Other revenues (ancillary energy and other income streams)
Competitive
Bristol-Myers Squibb Company segments
Full profile >Eliquis franchise (apixaban)
Oligopoly
Immuno-oncology checkpoint inhibitors (Opdivo/Yervoy/Opdualag)
Oligopoly
Hematology (Revlimid/Pomalyst/Reblozyl)
Competitive
Immunology (Orencia/Sotyktu)
Competitive
Other specialty & emerging products (CAR-T, cardiomyopathy, neuroscience, and mature brands)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.